
News|Articles|November 1, 2005
Pipeline Preview
Muraglitazar (Pargluva, Bristol-Myers Squibb, Merck) for the treatment of type 2 diabetes.
Advertisement
Approvable designations
Fast-track designations
Orphan drug designations
Non-approvable designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicare’s first-year payments for social needs showed high use by primary care but many claims were denied
2
See which Minnesota healthcare CEOs signed letter calling for 'immediate deescalation of tensions' following shooting of Alex Pretti
3
House passes funding bill that includes PBM reform
4
Do you know what’s in your contracts?
5




























